No­var­tis re­turns for an­oth­er piece of IFM Ther­a­peu­tics

Af­ter buy­ing a por­tion of IFM Ther­a­peu­tics’ pipeline in 2019, No­var­tis is back for a sec­ond help­ing as it bags its STING an­tag­o­nists.

The Swiss Big Phar­ma had paid $90 mil­lion up­front a few years ago for an op­tion and col­lab­o­ra­tion agree­ment and would pay up to $745 mil­lion in mile­stones if it opt­ed to ac­quire IFM’s sub­sidiary IFM Due.

Its time is due, and the com­pa­nies said Wednes­day that No­var­tis will have full rights to IFM Due’s port­fo­lio of STING an­tag­o­nists, which could turn in­to treat­ments for in­flam­ma­tion-dri­ven dis­eases. The deal is a re­sult of a four-year pre­clin­i­cal tie-up on small mol­e­cules.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER